Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trumenba in healthy children (2-9 years)
NCT02531698Phase 2
Key facts
- Status
- Completed
- Start
- Aug 2015
- Primary completion
- Mar 2017
- Countries
- 2
- Sponsor
- Pfizer
- Modality
- Vaccines & Immunotherapeutics
- Drugs
- meningococcal group B vaccine
- Conditions
- meningococcal disease
01
Overview
Phase 2, randomised, single-blind trial of meningococcal group B vaccine in meningococcal disease, sponsored by Pfizer. Primary endpoint: Percentage of Participants With Serum Bactericidal Assay Using Human Complement Titers >= Lower Limit of Quantitation. Started Aug 2015; status: completed.
02
Design
- Study design
- RandomizedSingle-blind
03
Who it enrols
Healthy children aged 2 to <10 years who have received all vaccinations in the relevant national immunization program.
04
Endpoints
Primary
Percentage of Participants With Serum Bactericidal Assay Using Human Complement Titers >= Lower Limit of Quantitation
Beyond the preview
Go deeper on NCT02531698.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02531698.